Mas­ter deal­mak­er? Medi­va­tion CEO David Hung’s overzeal­ous PARP as­sault falls flat

Medi­va­tion doesn’t look any fur­ther ahead now that the CEO is pub­licly de­fend­ing the as­set like a dog de­fends a bone

John Car­roll, Ed­i­tor

Back when David Hung was build­ing Medi­va­tion as a pipeline com­pa­ny, he per­suad­ed Pfiz­er to fork over $225 mil­lion as an up­front to part­ner on dime­bon, a Russ­ian an­ti­his­t­a­mine that had shown some ac­tiv­i­ty for Alzheimer’s in ear­ly stud­ies. Dime­bon went on to be­come an em­bar­rass­ing fi­as­co, fail­ing two ex­pen­sive Phase III stud­ies. And I can re­call Hung dis­count­ing the sig­nif­i­cance of the pro­gram to his com­pa­ny when he was be­tween late-stage flops. Af­ter all, he told me, Pfiz­er had paid for that work al­ready.

Hung and Medi­va­tion went on to glo­ry with Xtan­di, and the CEO clear­ly nev­er lost the abil­i­ty to tout ear­ly da­ta and look for an edge wher­ev­er he can find it. He is wide­ly re­gard­ed as one of the best deal­mak­ers in the busi­ness, and now that he’s bar­gain­ing over the sale of his com­pa­ny with Sanofi and like­ly Pfiz­er, Cel­gene and oth­ers, he’s pulling out all the stops to go for the high­est pos­si­ble price he can get – and then some.

That win-at-all-costs men­tal­i­ty was on dis­play Wednes­day evening, as Hung went to work on the one as­set he has with a wild­ly un­cer­tain val­ue: Medi­va­tion’s PARP in­hibitor ta­la­zoparib. Tak­ing a frag­ment of da­ta, he claimed that ta­la­zoparib was clear­ly the best of four con­tenders, far sur­pass­ing Tesaro’s ni­ra­parib, As­traZeneca’s Lyn­parza (ola­parib) and Ab­b­Vie’s veli­parib.

Ta­la­zoparib, he told an­a­lysts on a call, is a “multi­bil­lion-dol­lar op­por­tu­ni­ty.”

The drug, he ex­plained, is a PARP trap­per, far bet­ter at de­stroy­ing can­cer cells that an enyzme in­hibitor. There was more. Lots more. And he went far be­yond the com­pa­ny’s first stab at high­light­ing the drug’s spe­cial po­ten­tial.

David Hung, Medi­va­tion CEO

The oth­er drugs failed to mea­sure up, he said. There were safe­ty is­sues and so on. He said every­thing pos­si­ble that could build up the val­ue of ta­la­zoparib as the “best-in-class” op­por­tu­ni­ty in a de­vel­op­ing $30 bil­lion mar­ket. And he made a short at­tack on the com­pe­ti­tion as sor­ry, sec­ond-raters.

Here’s the full Pow­er­Point pre­sen­ta­tion.

Bot­tom line: If Sanofi ex­ecs think they can get that drug for a $3 CVR, they have to be dream­ing.

Medi­va­tion got this drug just a year ago, pay­ing out $410 mil­lion up­front. That’s a sig­nif­i­cant amount, and it suc­cess­ful­ly fo­cused a lot of at­ten­tion as the top prospect in the clin­ic. It cer­tain­ly war­rants more than the pass­ing men­tion re­served for pidilizum­ab, the PD-1 drug that em­bar­rass­ing­ly proved not to be a PD-1 drug. The FDA tem­porar­i­ly halt­ed work on a tri­al so reg­u­la­tors could get a bet­ter fix on the drug. (Medi­va­tion’s at­ti­tude: Hey, it works some­how, so it’s im­por­tant.)

The CEO is in the fight of his pro­fes­sion­al ca­reer. With the com­pa­ny in play, the best out­come for Hung here is that some­body pays a record price for his as­sets. And he’ll say any­thing to make that hap­pen.

The PARP war, though, is far from over. Medi­va­tion’s stock is up just a few cents this morn­ing. These bid­ders can as­sess the val­ue of a Phase III prospect as well as any­one. And Medi­va­tion doesn’t look any fur­ther ahead now that the CEO is pub­licly de­fend­ing the as­set like a dog de­fends a bone. If any­thing, he may have dam­aged his case by go­ing over­board on the zeal­ous as­sault.

— John Car­roll @John­Cendpts

UP­DAT­ED: Mer­ck pulls Keytru­da in SCLC af­ter ac­cel­er­at­ed nod. Is the FDA get­ting tough on drug­mak­ers that don't hit their marks?

In what could be an early shot in the battle against drugmakers that whiff on confirmatory studies to support accelerated approvals, the FDA ordered Bristol Myers Squibb late last year to give up Opdivo’s approval in SCLC. Now, Merck is next on the firing line — are we seeing the FDA buckling down on post-marketing offenders?

Merck has withdrawn its marketing approval for PD-(L)1 inhibitor Keytruda in metastatic small cell lung cancer as part of what it describes as an “industry-wide evaluation” by the FDA of drugs that do not meet the post-marketing checkpoints on which their accelerated nods were based, the company said Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

The global pandemic may have roiled economies, killed hundreds of thousands and throttled entire industries, but the only effect it had on biopharma venture investing was to help turbocharge the field to giddy new heights.

Below you’ll find the new top 100 venture investors in the industry, ranked by the number of deals they were publicly involved in, as tracked by DealForma chief Chris Dokomajilar. The numbers master then calculated the estimated amount of money they put into each deal — divvying up the cash by the number of players — to indicate how they managed their syndicates.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron, Endpoints UKBIO19

GSK, Vir's hopes for a Covid-19 an­ti­body fall flat in NIH 'mas­ter pro­to­col' with no ben­e­fit in hos­pi­tal­ized pa­tients

GlaxoSmithKline and Vir Biotechnology were hopeful that one of their partnered antibodies would carve out a win after getting the invite to a major NIH study in hospitalized Covid-19 patients. But just like Eli Lilly, the pair’s drug couldn’t hit the mark, and now they’ll be left to take a hard look at the game plan.

The NIH has shut down enrollment for GSK and Vir’s antibody VIR-7831 in its late-stage ACTIV-3 trial after the drug showed negligible effect in achieving sustained recovery in hospitalized Covid-19 patients, the partners said Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

As Brain­Storm con­tin­ues to tout ‘clear sig­nal’ on ALS drug, the FDA of­fers a rare pub­lic slap­down on the da­ta

A little more than a week after BrainStorm acknowledged that regulators at the FDA had informed them that the biotech needed more data before it could expect to gain an approval for its ALS treatment NurOwn — while still touting a “clear signal” of efficacy and not ruling out an application — the agency has decided to clarify the record in a most unusual statement.

The FDA statement amounts to a straight slap own, offering a different set of efficacy numbers from the company’s public presentation last November and ruling out any chance of statistical significance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

In­tro­duc­ing End­points FDA+, our new pre­mi­um week­ly reg­u­la­to­ry news re­port led by Zachary Bren­nan

CRLs. 483s. CBER, CDER and RWE. For biopharma professionals, these acronyms command attention because of the fundamental role FDA plays in drug development. Now Endpoints is doubling down on regulatory coverage, and launching a weekly report focusing on developments out of White Oak, with analysis and insight into what it all means.

Coverage will be led by our new senior editor, Zachary Brennan. He joins Endpoints from POLITICO, where he covered pharma. Prior to that he was the managing editor for Regulatory Focus, a news publication from the Regulatory Affairs Professionals Society.

Antoine Papiernik, Sofinnova managing director (Business Wire)

Sofinno­va Part­ners stays fo­cused on late-stage deals with a new, $540M crossover fund

One of Europe’s most high-profile biopharma investors is getting $540 million to invest in new crossover deals for late-stage companies.

The Paris-based VC says the fresh Sofinnova Crossover Fund raise positions them as the “largest crossover investor in Europe dedicated to late-stage biopharma and medtech investments.”

They got a leg up in France after winning a special “Tibi” designation from the French government, giving them access to a pool of €6 billion that helped them gain an edge with institutional investors. Since they were founded close to 50 years ago, the venture group has backed more than 500 companies and currently has more than €2 billion under management.

Presage teams with Mer­ck on its Phase 0 test­ing; Kem­Pharm AD­HD drug wins ap­proval in chil­dren aged 6 and up

Seattle-based Presage Biosciences, which approaches drug development through its microdosing platform, has some new partnerships and cash to come with them.

Presage closed a $13 million financing round Tuesday, aiming to expand its network of clinical trial sites and advance development of its microdosing injection devices. They also closed partnership deals with Merck and Maverick Therapeutics.

The financing included $7 million from new investors, including the LabCorp Venture Fund, Bristol Myers Squibb, and InHarv Partners. An additional $6 million convertible note from Takeda Ventures will convert to equity.

Eli Lil­ly claims suc­cess in a new JAK in­di­ca­tion: hair loss

Over the last decade, drugmakers have proven JAK inhibitors can treat a smattering of immune-related diseases ranging from rheumatoid arthritis to Covid-19. Now Eli Lilly has pulled out a new one.

Lilly and its biotech partner Incyte announced Wednesday that their JAK inhibitor baricitinib effectively regrew patients’ hair in a Phase III trial for alopecia areata, an autoimmune condition that can cause sudden, severe and patchy hair loss. Lilly didn’t break down the results from the 546-patient trial, but the primary endpoint was improvement on a standard score for alopecia symptoms.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

Thank you, next: Take­da hands Ovid $196M cash to rein back in Phase III-ready seizure drug, re­viv­ing bat­tered stock

Soticlestat made it.

Takeda is bringing the drug back into its fold more than four years after first entrusting the team at Ovid with the mid-stage clinical work. For all that — generating what they saw as positive Phase II data in Dravet syndrome and Lennox-Gastaut syndrome — the biotech has been rewarded with $196 million in upfront cash, with another $660 million reserved for regulatory and commercial milestones.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.